These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 362814)

  • 1. Uraemic toxins of high molecular weight inhibiting human mononuclear phagocytes cultured in vitro.
    Jörstad S; Kvernes S
    Acta Pathol Microbiol Scand C; 1978 Oct; 86C(5):221-6. PubMed ID: 362814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of plasma from uraemic patients on human mononuclear phagocytes cultured in vitro.
    Jorstad S; Viken KE
    Acta Pathol Microbiol Scand C; 1977 Jun; 85(3):169-77. PubMed ID: 327752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport of uremic toxins through conventional hemodialysis membranes.
    Jörstad S; Smeby LC; Wideröe TE; Berg KJ
    Clin Nephrol; 1979 Oct; 12(4):168-73. PubMed ID: 509791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of serum and plasma from haemodialysis patients on human mononuclear phagocytes cultured in vitro.
    Wessel-Aas T
    Acta Pathol Microbiol Scand C; 1981 Dec; 89(6):345-51. PubMed ID: 7336930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fibronectin on C3b and Fc receptor-mediated phagocytosis by peripheral blood monocytes in uraemic patients.
    Pertosa G; Mastrolitti G; Späth PJ; Fracasso AR; Manno C; Schena FP
    Nephrol Dial Transplant; 1989; 4(1):15-20. PubMed ID: 2522602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis.
    Vanholder R; De Smet R; Jacobs V; Van Landschoot N; Waterloos MA; Vogeleere P; Ringoir S
    Nephrol Dial Transplant; 1994; 9(9):1271-8. PubMed ID: 7816288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of conventional and high-performance liquid chromatographic techniques for the isolation of so-called "uraemic toxins".
    Brunner H; Mann H
    J Chromatogr; 1984 Aug; 297():405-16. PubMed ID: 6490772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Middle molecules separation from uraemic serum (author's transl)].
    Dall'aglio P; Buzio C; Gardini GP; Migone L
    Ateneo Parmense Acta Biomed; 1975; 46(5):331-44. PubMed ID: 1236694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of mistletoe ( Viscum album) extracts on phagocytosis/burst activity of human phagocytes.
    Frank U; Engels I; Wagner A; Lacour M; Daschner FD
    Eur J Clin Microbiol Infect Dis; 2003 Aug; 22(8):501-3. PubMed ID: 12884062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of uraemic toxins by haemofiltration with different membranes. The benefit of regenerating haemofiltrate using a newly developed system.
    Jörstad S; Smeby LC; Wideröe TE; Berg KJ
    Proc Eur Dial Transplant Assoc; 1979; 16():212-7. PubMed ID: 548983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparative isolation of middle molecular weight fractions from the hemofiltrate of patients with chronic uremia.
    Brunner H; Mann H; Essers U; Schultheis R; Byrne T; Heintz R
    Artif Organs; 1978 Nov; 2(4):375-7. PubMed ID: 743009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique.
    Davilas A; Koupparis M; Macheras P; Valsami G
    J Pharm Pharmacol; 2006 Nov; 58(11):1467-74. PubMed ID: 17132209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of middle molecules: clinical evaluation using a selective filtration artificial kidney.
    Jörstad S; Smeby LC; Wideröe TE
    Artif Organs; 1981; 4 Suppl():98-103. PubMed ID: 7295103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations on clinico-chemical correlations in uraemic polyneuritis.
    Man NK; Cueuille G; Zingraff J; Drueke T; Jungers P; Sausse A; Billon JP; Funck-Brentano JL
    Proc Eur Dial Transplant Assoc; 1975; 11():214-21. PubMed ID: 1197256
    [No Abstract]   [Full Text] [Related]  

  • 17. Analytical study for separation of middle molecules.
    Saito A; Kanazawa I; Chung TG; Maeda K
    Artif Organs; 1981; 4 Suppl():13-6. PubMed ID: 6975092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components.
    Kamata K; Okubo M; Sada M
    Clin Exp Immunol; 1983 Oct; 54(1):277-81. PubMed ID: 6616971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodology for identification of serum middle molecules.
    Buzio C; Montagna G; Calderini C; Manari A; Migone L
    Artif Organs; 1981; 4 Suppl():22-7. PubMed ID: 7295090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrocyte transport of middle molecular substances.
    Gajdos M; Spustová V; Geryková M; Dzúrik R
    Proc Eur Dial Transplant Assoc; 1981; 18():183-7. PubMed ID: 7329966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.